While BRCA1 promoter methylation is associated with HRD and is present in a subset of high-grade serous ovarian cancer (HGSOC) cases, findings from the TCGA study [21], indicate that BRCA1 promoter methylation was not highlighted as an independent prognostic marker for patient outcomes. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.